New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.
News & Analysis: Abiomed
Look for proven resilience and growth prospects on the horizon.
Abiomed is definitely not cheap, but there is significant upside left in this stock.
This company's medical products can help patients suffering from COVID-19's most dangerous complications.
Some of the names on this list may surprise you.
Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.
ABMD earnings call for the period ending June 30, 2020.
Investors registered heartfelt support for this biotechnology company.
The company is weathering a coronavirus-related shutdown, and a new purchase will help with diversification.
Investors were encouraged by the company's Q4 earnings beat.